Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II

Journal of Crohn's and Colitis

Volumn 3, Issue 4, 2009, Pages 241-249

  Juillerat, Pascal ^a,b   Vader, John Paul ^b   Felley, Christian ^a   Pittet, Valérie ^b   Gonvers, Jean Jacques ^a   Mottet, Christian ^a   Bemelman, Willem A ^c   Lémann, Marc ^d   Öresland, Tom ^e   Michetti, Pierre ^a   Froehlich, Florian ^a,f  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SAINT LOUIS HOSPITAL   (France)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Appropriateness; Crohn's disease; Inflammatory bowel disease; Maintenance treatment; RAND Appropriateness Method; Therapy

Indexed keywords

AZATHIOPRINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CROHN DISEASE; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL;

EID: 70350583962     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.05.002     Document Type: Article

References (63)

1. Baumgart D.C., and Sandborn W.J. Inflammatory bowel disease: 674 clinical aspects and established and evolving therapies. Lancet 369 9573 (2007) 1641-1657
2. Gonvers J.J., Juillerat P., Mottet C., et al. Maintenance of medically induced remission of Crohn's disease. Digestion 76 2 (2007) 116-129
3. Froehlich F., Juillerat P., Pittet V., et al. Maintenance of surgically induced remission of Crohn's disease. Digestion 76 2 (2007) 130-135
4. Pearson D.C., May G.R., Fick G., and Sutherland L.R. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000067
5. Pearson D.C., May G.R., Fick G.H., and Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123 2 (1995) 132-142
6. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 22 (2000) 1627-1632
7. Feagan B., McDonald J., Ponich T., Panaccione R., Enns R., and Bernstein C. A randomized trial of Methotrexate in combination with infliximab for the treatment of Crohn's disease (COMMIT trial). Gastroenterology 134 (2008) 682C (late breaking abstract)
8. Hanauer S., Sandborn W.J., Persson A., and Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 21 4 (2005) 363-371
9. Akobeng A.K., and Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 1 (2005) CD003715
10. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 18 (2005) 1912-1925
11. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 4 (2005) 362-368
12. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 4 (1999) 761-769
13. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (2002) 1541-1549
14. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 9 (2007) 1232-1239
15. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 1 (2007) 52-65
16. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135 5 (2008) 1493-1499
17. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 3 (2007) 239-250
18. Behm B.W., and Bickston S.J. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease. Cochrane Database Syst Rev 1 (2008) CD006893
19. Sandborn W., Lichtenstein G., Schreiber S., and Feagan B.G. The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for Crohn's disease. Am J Gastroenterol 103 S429 (2008) A1099
20. Panaccione R., Colombel J.F., Sandborn W.J., et al. Adalimumab maintains long-term remission in Crohn's disease through 2 years. J Crohn's Colitis 2 suppl.)(1 (2008) 5
21. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 2 (2004) 402-413
22. Peyrin-Biroulet L., Deltenre P., De Suray N., Branche J., Sandborn W., and Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association 6 6 (2008) 644-653
23. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 5 (2006) 621-630
24. Toruner M., Loftus Jr. E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 4 (2008) 929-936
25. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 7 (2008) 1861-1868
26. Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 2 (2007) 265-267
27. Shale M., Kanfer E., Panaccione R., and Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57 12 (2008) 1639-1641
28. Clark M., Colombel J.F., Feagan B.C., et al. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology 133 1 (2007) 312-339
29. Camma C., Giunta M., Rosselli M., and Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta- analysis adjusted for confounding variables. Gastroenterology 113 5 (1997) 1465-1473
30. Cottone M., and Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 119 2 (2000) 597
31. Camma C., Viscido A., Latella G., Caprilli R., and Cottone M. Mesalazine in the prevention of clinical and endoscopice postoperative recurrence of Crohn's disease: a meta-analysis. Dig Liver Dis 34 (2002) A86
32. D'Haens G.R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135 4 (2008) 1123-1139
33. Hellers G., Cortot A., Jewell D., et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 116 2 (1999) 294-300
34. Van Gossum A., Dewit O., Louis E., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 13 2 (2007) 135-142
35. Colombel J.F., Rutgeerts P., Malchow H., et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49 1 (2001) 42-46
36. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 2 (2009) 441-450
37. Mottet C., Juillerat P., Pittet V., et al. Upper gastrointestinal Crohn's disease. Digestion 76 2 (2007) 136-140
38. Mottet C., Juillerat P., Pittet V., et al. Pregnancy and breastfeeding in patients with Crohn's disease. Digestion 76 2 (2007) 149-160
39. Michetti P., Mottet C., Juillerat P., et al. Severe and steroid-resistant Crohn's disease. Digestion 76 2 (2007) 99-108
40. Michetti P., Juillerat P., Mottet C., et al. Mild-to-moderate active luminal Crohn's disease. Digestion 76 2 (2007) 92-98
41. Juillerat P., Pittet V., Felley C., et al. Drug safety in Crohn's disease therapy. Digestion 76 2 (2007) 161-168
42. Juillerat P., Mottet C., Pittet V., et al. Extraintestinal manifestations of Crohn's disease. Digestion 76 2 (2007) 141-148
43. Froehlich F., Juillerat P., Mottet C., et al. Fibrostenotic Crohn's disease. Digestion 76 2 (2007) 113-115
44. Felley C., Mottet C., Juillerat P., et al. Fistulizing Crohn's disease. Digestion 76 2 (2007) 109-112
45. Vader J.P., Froehlich F., Juillerat P., et al. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach-EPACT. Digestion 73 4 (2006) 237-248
46. Juillerat P., Froehlich F., Felley C., et al. EPACT II: project and methods. Digestion 76 2 (2007) 84-91
47. Brook R.H., Chassin M.R., Fink A., Solomon D.H., Kosecoff J., and Park R.E. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 2 1 (1986) 53-63
48. Fitch K., Bernstein S.J., Aguilar M.S., et al. The RAND/UCLA Appropriateness Method User's Manual (2001), RAND Corporation
49. Steinhart A.H., Hemphill D., and Greenberg G.R. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 89 12 (1994) 2116-2124
50. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 4 (2009) 492-500
51. Colombel J., Rutgeerts P., Reinisch W., et al. SONIC: a randomized, double-blind, controlled trial compraing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 57 suppl. II (2008) A1
52. Schreiber S. Long term treatment with certolizumab pegol for up to 18 months of in patient with active Crohn's disease: precise 3 efficacy results. Gastroenterology 132 4 (suppl. I) (2007) A504
53. Caprilli R., Cottone M., Tonelli F., et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 17 4 (2003) 517-523
54. Regueiro M. Management and Prevention of Postoperative Crohn's Disease. Inflamm Bowel Dis in press.
55. Travis S.P., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
56. Stange E.F., Travis S.P., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 Suppl 1 (2006) i1-i15
57. Caprilli R., Gassull M.A., Escher J.C., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 Suppl 1 (2006) i36-i58
58. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American Gastroenterological Association Institute Technical Review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 3 (2006) 940-987
59. Sandborn W.J., Lofberg R., Feagan B.G., Hanauer S.B., Campieri M., and Greenberg G.R. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100 8 (2005) 1780-1787
60. Hanauer S.B., and Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 96 3 (2001) 635-643
61. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 3 (1976) 439-444
62. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 2 (2002) 512-530
63. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., and Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 4 (1990) 956-963